Sesen Bio Inc.

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in April 2016 and is headquartered in Philadelphia, PA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company will host a conference call with Dr. Neal Shore, medical director of the Carolina Urologic Research Center who will provide a clinical perspective on Vicineum, Sesen Bio's product candidate for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). I

Sesen Bio Announces Conference Call with Neal Shore, M.D., FACS to Provide Clinical Perspective on the Company's Lead Product Candidate Vicineum™

The FDA has provided Vicineum a priority review and an August 2021 PDUFA date. Following the headline, Sesen Bio's share price spiked to a new 52-week high. Now with an accelerated timeline and no AdCom, Sesen can prepare for a potential 2021 commercial launch. As a result, I am looking to hold my position through the PDUFA.

Sesen Bio: Vicineum's Priority Review Provides Conviction To Hold Through PDUFA Date

Sesen Bio's vicinium is targeting a form of NMIBC. Its chief competitor is adstiladril, and its current position with the FDA is a bit vague.

Sesen Bio: Problems Of Main Competitor Make Vicinium More Attractive

The FDA accepted the company's filing for approval of Vicineum in treating bladder cancer.

Why Sesen Bio Stock Is Soaring Today

Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading lower Tuesday after the company priced its 44.2 million share common stock offering at $2 per share. Hepion Pharmaceuticals Inc is engaged in the development of targeted pharmaceutical therapies for liver disease.

Why Hepion Pharma, Sesen Bio And More Are Moving Today

Under priority review status, the FDA has accepted Sesen Bio Inc's (NASDAQ: SESN) marketing application for review seeking approval for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer. Additionally, the FDA stated that it is not currently planning to hold an advisory committee meeting to discuss the application.

Sesen Bio's Vicineum US Application For Bladder Cancer Accepted For Review; Shares Spike

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, announced today that the U.S. Food and Drug Administration (FDA) accepted for filing the Company's Biologics License Application (BLA) for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and granted the application Priority Review. In addition, the FDA stated tha

Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell, President and CEO will host a conference call on Tuesday, February 16, 2021 at 8:00 a.m. ET to provide a business update. To participate in the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) and refer to conference ID 1290313. The web

Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide a Business Update

Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Sesen Bio (SESN) Surges: Stock Moves 6.4% Higher

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that on January 29, 2021 the Company participated in a productive Application Orientation Meeting with the FDA regarding its Biologic License Application (BLA) for Vicineum, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). After the Company submitted its BLA to the FDA

Sesen Bio Announces Successful Application Orientation Meeting (AOM) with the FDA for Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that the Investigational New Drug (IND) application submitted to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) by the Company's partner in China, Qilu Pharmaceutical, was accepted for review. If the IND is approved, Qilu will be authorized to conduct

Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum™ Accepted for Review by the National Medical Products Administration in China

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced submission of the completed Biologics License Application (BLA) to the FDA for Vicineum for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) on December 18, 2020. Within 60 days after receipt of the completed application, the FDA will issue a decision to the Com

Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum™ and Has Requested Priority Review

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced favorable results for the cost-effectiveness of Vicineum based on an independent analysis issued by ICER in its final report published on December 17, 2020. ICER is the leading Health Technology Assessment body in the United States, and is an independent non-profit, research organization that conduct

Sesen Bio Announces Positive Cost-Effectiveness Profile for Vicineum™ Based on the Final Evidence Report Issued by the Institute for Clinical and Economic Review (ICER)

Sesen Bio (SESN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Sesen Bio (SESN) Surges: Stock Moves 7.8% Higher

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on Friday, December 4, 2020 the Company entered into a commercial manufacturing and supply framework agreement (the “CMO Agreement”) with the Company's partner in China, Qilu Pharmaceutical Co., Ltd. (“Qilu”). Under the CMO Agreement, Qilu will be part of the contract manufacturing network for g

Sesen Bio Announces Commercial Manufacturing and Global Supply Partnership with Qilu Pharmaceutical

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals, a multi-national pharmaceutical company and leading licensing partner in the Middle East and North Africa (“MENA”) region specializing in the development and commercialization of a broad range of high-quality medicines, today announced that the companies have entered into an exclusive lice

Sesen Bio Announces Partnership with Hikma Pharmaceuticals for the Commercialization of Vicineum™ in the Middle East and North Africa

Sesen Bio, Inc. (SESN) CEO Thomas Cannell On Q3 2020 Results - Earnings Call Transcript

Sesen Bio, Inc.'s (SESN) CEO Thomas Cannell on Q3 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the third quarter ended September 30, 2020. The Company's lead program, VicineumTM, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December

Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the BLA Submission for VicineumTM in December 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call on Monday, November 9, 2020 at 8:00 a.m. ET to review operating results for the third quarter ended September 30, 2020. The Company will also provide an update on the progress of studies related to assessing analytical comparability between clinical

Sesen Bio to Host Conference Call to Review Third Quarter Financial Results and Provide an Update on Positive Progress Towards Demonstration of Analytical Comparability

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has completed a successful pre-submission meeting with the European Medicines Agency (“EMA”) for Vicineum1 for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”) in Europe. During the meeting, the EMA addressed product-specific, legal, regulatory and scientific top

Sesen Bio Announces Successful Pre-Submission Meeting with the European Medicines Agency for Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company has selected Cardinal Health as its exclusive provider for third-party logistics (3PL) and specialty pharmaceutical distribution services related to the commercial distribution of Vicineum in the United States (U.S.). The Company's lead program, Vicineum, also known as VB4-845, is cur

Sesen Bio Announces an Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharmaceutical Distribution Services for Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H.

Sesen Bio to Provide Business Update at the H. C. Wainwright 22nd Annual Global Investment Conference

Sesen Bio (SESN) Looks Good: Stock Adds 6.2% in Session

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the second quarter ended June 30, 2020.

News for Sesen Bio Inc. Stock (SESN)